Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases

NCT04801342 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Malignant Neoplasm to Brain

Interventions

RADIATION: Conformal Whole Brain Radiotherapy with Unilateral Hippocampal Avoidance
RADIATION: Conformal Whole Brain Radiotherapy with Bilateral Hippocampal Avoidance
DRUG: Memantine Hydrochloride

Sponsor

National Taiwan University Hospital